Cipher Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Cipher Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 13.5% en 8.7% per jaar. De winst per aandeel zal naar verwachting groeien met 12.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11% zijn.

Belangrijke informatie

13.5%

Groei van de winst

12.86%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	39.8%
Inkomstengroei	8.7%
Toekomstig rendement op eigen vermogen	10.95%
Dekking van analisten	Low
Laatst bijgewerkt	09 May 2025

Recente toekomstige groei-updates

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

Recent updates

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

May 09

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Apr 28

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

Feb 23 Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Dec 13

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Nov 14

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Nov 12

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26

Winst- en omzetgroeiprognoses

TSX:CPH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2027	62	19	N/A	24	2
12/31/2026	58	17	N/A	25	3
12/31/2025	51	14	N/A	25	3
3/31/2025	40	9	-59	21	N/A
12/31/2024	33	12	-60	20	N/A
9/30/2024	26	16	-67	13	N/A
6/30/2024	22	23	17	17	N/A
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	4	6	N/A
3/31/2019	23	3	0	2	N/A
12/31/2018	23	1	N/A	8	N/A
9/30/2018	28	6	N/A	13	N/A
6/30/2018	34	9	N/A	18	N/A
3/31/2018	37	11	N/A	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A
9/30/2014	33	31	N/A	23	N/A
6/30/2014	32	27	N/A	18	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei CPH ( 13.5% per jaar) ligt boven de spaarquote ( 2.4% ).

Winst versus markt: De winst van CPH ( 13.5% per jaar) zal naar verwachting langzamer groeien dan de markt Canadian ( 13.9% per jaar).

Hoge groeiwinsten: De winst van CPH zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van CPH ( 8.7% per jaar) zal naar verwachting sneller groeien dan de markt Canadian ( 4.8% per jaar).

Hoge groei-inkomsten: De omzet van CPH ( 8.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen CPH zal naar verwachting over 3 jaar laag zijn ( 11 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/05/12 02:57
Aandelenkoers aan het einde van de dag	2025/05/12 00:00
Inkomsten	2025/03/31
Jaarlijkse inkomsten	2024/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Cipher Pharmaceuticals Inc. wordt gevolgd door 13 analisten. 3 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Douglas Loe	Byron Capital Markets
Tania Armstrong-Whitworth	Canaccord Genuity
Prakash Gowd	CIBC Capital Markets

Cipher Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 7.0% to CA$15.65

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 7.4% to CA$17.37

Consensus EPS estimates increase by 10%

Consensus revenue estimates increase by 37%

Recent updates

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025

Investor sentiment improves as stock rises 20%

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025

Price target decreased by 7.0% to CA$15.65

Lead Independent Director exercised options and sold CA$64k worth of stock

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Investor sentiment deteriorates as stock falls 15%

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 7.4% to CA$17.37

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus revenue estimates increase by 37%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to CA$3.30

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations